Keywords: UK, NICE, Novartis, Bristol-Myers Squibb, Tasigna, Sprycel, Glivec, Afinitor

UK’s NICE says “no” to Novartis Tasigna and B-MS Sprycel, but better news on Afinitor

Article | 06 May 2011

Print This

The UK’s drug rationing body the National Institute for Health and Clinical Excellence (NICE) yesterday published its new ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in